

Treatment strategy for maxillary gingival metastasis arising from gastric adenocarcinoma: A case report and literature review

HITOSHI MIYASHITA¹, MASAKI SUGAZAKI¹, HARUKA SAITO², CHIEKO KUDO³, MUNENORI NAGAO⁴, YOJIRO ISHIKAWA⁵, SATOSHI TERAMURA⁵, FUMIAKI SHINOHARA¹ and KAZUHIRO MURAKAMI²

¹Department of Dentistry and Oral Surgery, Tohoku Medical and Pharmaceutical University Hospital, Sendai 983-8512, Japan;

²Department of Pathology, Tohoku Medical and Pharmaceutical University Hospital, Sendai 983-8512, Japan; ³Department of Medical Oncology, Tohoku Medical and Pharmaceutical University Hospital, Sendai 983-8512, Japan; ⁴Department of Supportive Medicine and Care for Cancer, Tohoku Medical and Pharmaceutical University Hospital, Sendai 983-8512, Japan; ⁵Department of Radiology, Tohoku Medical and Pharmaceutical University Hospital, Sendai 983-8512, Japan

Received April 28, 2024; Accepted February 6, 2025

DOI: 10.3892/mco.2025.2836

Abstract. Gastric cancer metastasizing to the gingiva is rare. The present study reports a case of maxillary gingival metastasis arising from gastric cancer treated with chemotherapy, surgical excision and radiotherapy. A 55-year-old male, who received chemotherapy with trifluridine/tipiracil for treatment of refractory gastric cancer with multiple metastasis, was admitted to the Department of Dentistry and Oral Surgery, Tohoku Medical and Pharmaceutical University Hospital (Sendai, Japan) in December 2023 because of the right side of the maxillary gingival mass presenting with protruding growth. The size of the tumor was ~20 mm. Tumor excision was performed followed by histopathological diagnosis which revealed a metastatic gingival tumor originating from gastric adenocarcinoma. Consequently, the patient underwent a palliative Radiation Therapy Oncology Group 8502 'QUAD shot' regimen. Although there was no progression of oral lesion, the patient died 3 months after diagnosis of gingival metastasis. The present study reviewed previous case records of gingival metastasis originating from gastric cancer and summarized treatment modalities along with clinicopathological association. In conclusion, the prognosis of patients with metastases to the oral region (MOR) is usually unfavorable. For the

management of MOR, a multidisciplinary team approach is necessary to develop appropriate treatment strategies. If there are possibilities to improve prognosis or quality of life, the consideration of combination therapy with radical or palliative intent is warranted.

Introduction

Metastases to the oral region (MOR) are rare and represent 1-3% of all oral malignancies (1,2). The occurrence of MOR is associated with unfavorable prognosis and diminished overall survival (1-6). The anatomical regions most affected by MOR are the posterior mandible and, when it is in soft tissue, the gingiva (1-6). The clinical symptoms of MOR include pain, swelling, local bleeding due to ulceration and mass formation (4-7). The predominant primary sites of MOR are the lung, breast and kidney (1,4-6,8-11). Although gastric cancer is the fourth leading cause of cancer-associated mortality (12), the stomach counts for only ~2.5% of all primary cancer sites discovered in patients with MOR (5,6). There is currently no effective treatment for cases of gastric cancer metastasizing to the gingiva. To the best of our knowledge, including the present case, 23 cases (13-34) with gingival metastases from gastric cancer have been reported in English and Japanese literature. The present study, which was created based on the Surgical Case Report 2023 guideline (35), presents a rare case of gastric adenocarcinoma metastasizing to the maxillary gingiva treated with combination therapy comprising chemotherapy, tumor excision and Radiation Therapy Oncology Group 8502 'QUAD shot' radiotherapy (RT).

Case report

A 55-year-old male was referred to the Department of Dentistry and Oral Surgery, Tohoku Medical and Pharmaceutical University Hospital (Sendai, Japan) to examine the gingival swelling and the mobility of the right maxillary second molar in December 2023. In September 2021, the patient had been diagnosed with gastric

Correspondence to: Professor Hitoshi Miyashita, Department of Dentistry and Oral Surgery, Tohoku Medical and Pharmaceutical University Hospital, 1-12-1, Fukumuro, Miyagino, Sendai 983-8512, Japan
E-mail: miyashita@dent.tohoku.ac.jp

Abbreviations: RT, radiotherapy; FTD/TPI, trifluridine/tipiracil; MOR, metastases to oral region; QOL, quality of life; RAM, ramucirumab; ECOG-PS, Eastern Cooperative Oncology Group-performance status; CT, computed tomography; SUV, standardized uptake value; HNC, head and neck cancer

Key words: MOR, maxillary gingiva, gastric cancer, combination therapy, QUAD shot

adenocarcinoma with multiple regional lymph nodes and liver metastases. According to the Japanese Classification of Gastric Carcinoma 2017 (15th edition) (36), the clinical diagnosis was cT4aN2M1, stage IVB. Although the patient exhibited hepatic dysfunction that appeared to be associated with liver metastases, there was no other remarkable medical history. Serum levels of carcinoembryonic antigen (normal range, <5 ng/ml) and carbohydrate antigen 19-9 (normal range: <37 U/ml) were 2.5 ng/ml and <2 U/ml, respectively.

The patient underwent chemotherapy at the Outpatient Chemotherapy Center of the Department of Medical Oncology, Tohoku Medical and Pharmaceutical University Hospital (Sendai, Japan). Based on the Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) (37), two cycles of cisplatin (60 mg/m²) + tegafur-gimeracil-oteraci (80 mg/m²) was administered as first-line treatment for gastric cancer over a period of two months. Subsequently, the patient received chemotherapy with second-line weekly paclitaxel (PTX; 80 mg/m²) + ramucirumab (RAM; 8 mg/kg) for 16 cycles over a period of five months, followed by weekly administration of nanoparticle albumin-bound PTX (100 mg/m²) + RAM (8 mg/kg) for 31 cycles for thirteen months, third-line nivolumab (240 mg) for two cycles for one month and fourth-line irinotecan (150 mg/m²) for three cycles for four months. In each cycle of chemotherapy, doses were adjusted as appropriate based on the patient condition and white blood cell and platelet counts. However, these cancer chemotherapies were unsuccessful.

Upon admission, the patient received chemotherapy with trifluridine/tipiracil (FTD/TPI; 35 mg/m²) for three cycles for 2 months. Eastern Cooperative Oncology Group-performance status (ECOG-PS) scale (ecog-acrin.org/resources/ecog-performance-status/) was grade 2. The swelling had grown rapidly for ~3 weeks since the patient noticed the localized lesion and tooth mobility in October 2023. The patient also complained of frequent gingival bleeding when eating and brushing teeth. No palpable enlarged cervical lymph node was observed. The maximal mouth opening was 35 mm. Intraoral examination revealed a partially necrotic tumor with exophytic growth, ~20 mm in size, on the gingiva of the right maxillary posterior (Fig. 1). The mobility of the right maxillary second molar was severe.

Panoramic radiography showed bone resorption around the maxillary molar region (Fig. 2A). Computed tomography (CT; tube voltage, 120 kVp; exposure time, 2.25 sec; scanning length, 225 s; slice thickness, 1 mm) showed a mass with irregular bony destruction of the right side of the posterior maxilla with soft tissue density in the maxillary sinus (Fig. 2B). There was no evidence of cervical lymphadenopathy. Fluorodeoxyglucose positron-emission tomography/CT in September 2021 showed increased accumulation in the stomach [standardized uptake value (SUV)max 6.2] with regional lymph nodes (SUVmax ~3.4) and liver (SUVmax 9.2 and 9). On the other hand, there was no accumulation in the oral region (Fig. 3).

Due to rapid growth of the gingival tumor, which was often accompanied by local hemorrhage, the patient underwent surgical excision of the gingival tumor with concomitant removal of the right maxillary second molar to decrease symptoms in December 2023. The procedure was performed while the patient was receiving chemotherapy with FTD/TPI.

The tissue samples of the gastric cancer and the gingival tumor were fixed in 10% formalin neutral buffer solution and



Figure 1. Metastatic tumor with an exophytic growth on the right side of maxillary gingiva.

embedded in paraffin. Histological sections with a thickness of 4 μ m were stained with hematoxylin and eosin (H&E) and immunohistochemistry using Tissue-Tek Prisma Plus Automated Slide Stainer (Sakura Finetek Japan Co., Ltd.) and VENTANA BenchMark ULTRA system (Roche Diagnostics K.K), respectively. The sections were incubated with rabbit antibody against CD10, CK7 and CK20 and with mouse antibody against MUC (mucin) 2, MUC5AC and MUC6. H&E staining of the specimens from gingival tumors (Fig. 4A) and gastric cancer (Fig. 4B) demonstrated poorly differentiated adenocarcinoma. Immunohistochemical expression of human epidermal growth factor receptor 2 in gastric cancer was negative. Immunohistochemistry showed that both specimens were positive for CD10 (Fig. 4C and D) and CK7 (Fig. 4E and F) but negative for CK20, MUC2, MUC5AC and MUC6. These pathological findings revealed metastatic adenocarcinoma of maxillary gingiva that was consistent with a gastric cancer origin.

Although no bleeding from the tumor was reported since the procedure was completed, RT was planned to inhibit tumor regrowth. At 2 weeks following the surgical excision, the gingival tumor showed growth and the patient was treated with one cycle of palliative QUAD shot RT immediately. A total of two daily fractions of 3.5 Gy was delivered with an interval of ≥ 6 h for 2 consecutive days, totaling 14 Gy over four fractions. After that, there was no progression of maxillary gingival metastatic lesion and the patient was capable of oral intake. However, the patient died of multiple organ failure caused by systemic metastases 3 months following the diagnosis of maxillary gingival metastasis originating from gastric cancer.

Discussion

The incidence of gingival metastasis originating from gastric cancer is rare. English literature in PubMed (pubmed.ncbi.nlm.nih.gov/), Scopus (<https://www.scopus.com/>) and Google Scholar(scholar.google.com/) and Japanese literature in J-Stage (jstage.jst.go.jp/) were searched without date limit. The keywords 'oral region', 'gastric cancer' and 'metastasis'




Figure 2. Radiographic appearance of metastatic maxillary gingival lesion. (A) Panoramic radiography showing bone resorption of the affected area (arrow head). (B) Computed tomography image showing bone destruction and a mass formation of the right side of maxilla.

were searched in the title/abstract of publications. Studies cited by the review of Wu *et al* (32) and references of the included articles were also searched (Table I).

To the best of our knowledge, 23 cases including the present case have been reported to date in English and Japanese literature. Among these, ~43% (10/23 cases) were reported in Japan, indicating that such cases are more common compared with in other countries. This tendency may be due not only to advances in multimodal therapies globally but also from the progression of the Japanese super-aging society (5).

The present case exhibits features which align with those from previous reports: MOR is primarily observed in elderly patients, with a mean age of 57 years (5,6). The patient in the present case was 55-years-old, consistent with this age distribution. Secondly, the location of the MOR was the maxillary molar gingiva, a common site for gingival metastasis (4-6). In soft tissue, the attached gingiva is the most affected site because of chronic inflammation due to periodontitis (1,2,4,32). Allon *et al* (38) reported that in dentulous patients with gingival metastasis, metastatic foci were adjacent to teeth and the presence of teeth was significantly associated with gingival metastasis. When teeth are present, chronic inflammation may provide a niche for metastases (2,38,39). Shimono *et al* (5) suggested that chronic inflammation such as gingivitis causes MOR and gingival metastasis is likely to occur in the attached gingiva of remaining teeth. In the present case, the metastatic lesion was attached to the gingiva of the right maxillary molar. Thirdly, metastatic foci of the oral region sometimes show



Figure 3. Fluorodeoxyglucose-Positron Emission Tomography/computed tomography image in September 2021. The white arrows indicate hyper-accumulation in stomach (SUVmax 6.2), regional lymph nodes (SUVmax ~3.4) and liver (SUVmax 12 and 9.2), respectively (arrows). SUV, Standardized uptake value.

rapid growth (7,32). Here, gingival tumor presented as a nodule with local hemorrhage and enlarged rapidly within a month. Fourthly, MOR is typically accompanied by metastases of other sites (7,32,40). In the present case, gastric cancer was already accompanied by metastases of multiple lymph nodes and liver at first examination. Finally, prognosis of patients with MOR is poor and ~70% of patients die within 1 year of diagnosis of MOR (4). A review showed that the range of the mean time between the diagnosis of MOR and death is 7.5-9.8 months (5). In cases of gingival metastasis from gastric cancer, ~60% of patients die within 6 months of diagnosis (32). In the present case report, although the patient was treated with combination therapy, he died 3 months following diagnosis of maxillary gingival metastasis.

Chemotherapy alone, with palliative intent, is utilized in ~40% of patients with MOR and ~30% of the cases are treated

Table I. Cases with gingival metastasis originated from gastric cancer.

First author, year	Age/sex	Gingival site	Duration between primary gastric cancer and gingival meta	Other metastasis	Treatment	Vital status, time	(Refs.)
Lund <i>et al</i> , 1968	63/F	Mand	Synchronous	+	S	Died, 2 months	(13)
Astacio <i>et al</i> , 1969	58/M	Mand	Synchronous	ND	C	Died, 4 months	(14)
Ohba <i>et al</i> , 1974	51/M	Mand	Synchronous	+	RT	Died, 7 months	(15)
Lopez <i>et al</i> , 1976	65/F	Maxi	Before primary, 3 weeks	+	-	Died, ND	(16)
Osaki <i>et al</i> , 1978	59/M	Maxi	ND	ND	S	ND	(17)
Tojo <i>et al</i> , 1989	69/M	Mand	ND	ND	C	Died, 5 months	(18)
Hamakawa <i>et al</i> , 1993	56/M	Mand	ND	+	S	Died, 4 months	(19)
Florio <i>et al</i> , 1995	66/M	Maxi	After primary, 3 months	-	RT	Died, ND	(20)
Makino <i>et al</i> , 1997	60/M	Mand	ND	ND	C	Died, 4 months	(21)
Yajima <i>et al</i> , 1999	65/M	Maxi	ND	-	S	ND	(22)
Shimoyama <i>et al</i> , 2004	56/M	Mand	After primary, 15 months	+	-	Died, 3 months	(23)
Colombo <i>et al</i> , 2005	61/F	Maxi	Before primary, 7 months	-	C, RT	Died, 15 months	(24)
Kwon <i>et al</i> , 2006	65/M	Mand	Synchronous	-	-	Died, 3 months	(25)
Nishide <i>et al</i> , 2006	82/F	Mand	After primary, 4 years	+	S	ND	(26)
Hwang <i>et al</i> , 2007	58/M	Maxi	After primary, 4 years	+	C	ND	(27)
Uchiyama <i>et al</i> , 2009	73/F	Mand	After primary, 10 months	+	C, RT	Died, 9 months	(28)
Suaerbom <i>et al</i> , 2011	70/M	Mand	After primary, 3 months	+	S	Died, 3 months	(29)
Guo <i>et al</i> , 2012	62/F	Mand	After primary, 2 years	+	-	Died, 6 months	(30)
Kalaitsidou <i>et al</i> , 2015	71/M	Mand	After primary, 2 years	ND	S	ND	(31)
Wu <i>et al</i> , 2017	75/M	Maxi	After primary, 2.5 years	+	C, RT	Alive, 9 months	(32)
Soares <i>et al</i> , 2018	43/M	Mand	Before primary, ND	ND	C, RT	Died, 3 months	(33)
Ayşegu <i>et al</i> , 2018	54/M	Maxi	Before primary, ND	+	S, C	Died, 5 months	(34)
Present case, 2023	55/M	Maxi	After primary, 2 years	+	C, S, RT	Died, 3 months	

F, female; M, male; Mand, mandible; Maxi, maxilla; ND, not defined; +, with other metastasis; -, without other metastasis; S, surgery; C, chemotherapy; RT, radiotherapy; Before primary, detection of gingival metastasis before primary gastric cancer; After primary, detection of gingival metastasis after primary gastric cancer.

with combination therapy (5). For the treatment of gingival metastasis from gastric cancer, ~30% (7/23) of cases underwent surgical excision only (13,17,19,21,26,29,31) and 17% (4/23) of cases received chemotherapy alone (14,18,21,27). On the other hand, 26% (6/23) of cases were treated with combination therapy: 17% (4/23) received chemotherapy and RT (24,28,32,33), 4% (1/23) underwent surgery and chemotherapy (34), and one patient (4%) case underwent chemotherapy, tumor excision and RT. However, 12/23 (52%) of cases resulted in patient death within 6 months (13-34). Despite treatment modalities, there is currently no effective treatment for patients with MOR.

Treatment for MOR primarily focuses on improving patient quality of life (QOL) or prognosis through palliative care (2-5). Before treating MOR, it is necessary to evaluate the following factors: i) Patient prognosis; ii) patient condition, including ECOG-PS score; iii) existence of oral dysfunction or symptom; iv) whether the primary tumor is under control; v) progress of metastatic foci of the oral region and vi) patient will and intention in a multidisciplinary team approach.

Radiation Therapy Oncology Group 8502 'QUAD shot', which is a hypofractionated RT technique for palliative treatment, involves 2 days of twice-daily fractionation with a




Figure 4. Histopathological examination. (A) Metastatic maxillary gingival tumor and (B) primary gastric cancer demonstrated poorly differentiated adenocarcinoma. Immunohistochemistry revealed that (C) gingival tumor and gastric cancer (D) were positive for CD10. CK7 was also positive in the gingival tumor (E) and gastric cancer (F). Magnification, x200.

fraction size of 3.0-3.7 Gy (14.0-14.8 Gy/cycle). If possible, this regimen is repeated at 3-6-week intervals for a total of three cycles with an RT dose of 44.4 Gy (41,42). QUAD shot has been widely adopted for palliative treatment in patients with head and neck cancer (HNC) due to superior response rate, palliation, mild adverse effects and minimizing physical and social burdens (41-43). The National Comprehensive Cancer Network guidelines recommend the QUAD shot regimen as a palliative RT care for HNC (44).

Due to rapid growth of the gingival tumor and associated local hemorrhage in the present case, tumor excision was

performed in addition to chemotherapy. This approach was used to alleviate these symptoms rather than completely cure the gingival metastatic lesion. The patient received one cycle of palliative QUAD shot. After that, there was no tumor progression or local hemorrhage and the patient was capable of oral intake. However, the patient died of systemic metastasis after 3 months following diagnosis of maxillary gingival metastasis originating from gastric cancer.

The lesions of MOR are treatment-resistant and often demonstrate rapid progression. Moreover, lesions frequently lead to various symptoms and dysfunctions such as local

hemorrhage, pain, hypoesthesia, difficulty in oral intake, dysphagia and airway compromise (5,8,45). Most lesions of MOR are reported as nodules, with ~64% of cases being symptomatic (5). For these reasons, MOR should be managed to alleviate symptoms and improve or maintain patient QOL.

In the future, the number of patients with MOR is expected to increase (4,6). The presence of MOR is rarely found while treating the primary tumor and clinical symptoms appear in advanced stages. Physicians should check the symptoms of the oral region and perform screening during cancer therapy. The present study reported a case of maxillary gingival metastasis originating from gastric cancer and summarized relevant literature. The prognosis of MOR is usually unfavorable. It is important to detect MOR as early as possible to facilitate appropriate treatment. If there are opportunities to improve patient QOL or prognosis, physicians should develop treatment strategies with interdisciplinary teams. Combination therapy, including chemotherapy, immunotherapy, surgery and RT, such as QUAD shot, should be considered.

Acknowledgements

Not applicable.

Funding

The present study was supported by Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research (grant no. 23K09389).

Availability of data and materials

The data generated in the present study are not publicly available due to patient confidentiality but may be requested from the corresponding author.

Authors' contributions

HM designed the study, wrote the manuscript and performed the literature review. HM, MS, and FS collected and analyzed the data and prepared figures and tables. HS, CK, MN, YI, ST and KM supervised the study, analyzed data and edited the manuscript. HM, HS, CK, MN, YI and ST confirm the authenticity of all the raw data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

This case report was approved by Ethics Committee of Tohoku Medical and Pharmaceutical University Hospital (approval no. 2023-4-074).

Patient consent for publication

The patient provided written informed consent for publication of the case report and images.

Competing interests

The authors declare that they have no competing interests.

References

1. Hirshberg A and Buchner A: Metastatic tumours to the oral region. An overview, Eur J Cancer Part B Oral Oncol 31B: 355-360, 1995.
2. Hirshberg A, Shnaiderman-Shapiro A, Kaplan I and Berger R: Metastatic tumours to the oral cavity-pathogenesis and analysis of 673 cases. Oral Oncol 44: 743-752, 2008.
3. Hirshberg A, Berger R, Allon I and Kaplan I: Metastatic tumors to the jaws and mouth. Head Neck Pathol 8: 463-474, 2014.
4. Kirschnick LB, Schuch LF, Cademartori MG and Vasconcelos ACU: Metastasis to the oral and maxillofacial region: A systematic review. Oral Dis 28: 23-32, 2022.
5. Shimono H, Hirai H, Oikawa Y, Mochizuki Y, Kuroshima T, Tomioka H, Kayamori K, Ikeda T and Harada H: Metastatic tumors in the oral region: A retrospective chart review of clinical characteristics and prognosis. Oral Surg Oral Med Oral Pathol Oral Radiol 132: 648-652, 2021.
6. Kirschnick LB, Schuch LF, Gondak R, Rivero ERC, Gomes APN, Etges A, Tarquinio SBC, Mesquita RA, Caldeira PC, da Costa AAS, *et al*: Clinicopathological features of metastasis to the oral and maxillofacial region-multicenter study. Head Neck Pathol 17: 910-920, 2023.
7. Kajita T, Miyashita H, Kitamura J, Kouketsu A, Kumamoto H and Takahashi T: Pulmonary pleomorphic carcinoma metastasizing to the anterior mandibular gingiva: A case report and literature review. Int J Surg Case Rep 98: 107499, 2022.
8. Zachariades N: Neoplasms metastatic to the mouth, jaws and surrounding tissues. J Craniomaxillofac Surg 17: 283-290, 1989.
9. Maschino F, Guillet J, Curien R, Dolivet G and Bravetti P: Oral metastasis: A report of 23 cases. Int J Oral Maxillofac Surg 42: 164-168, 2013.
10. Jham BC, Salama AR, McClure SA and Ord RA: Metastatic tumors to the oral cavity: A clinical study of 18 cases. Head Neck Pathol 5: 355-358, 2011.
11. Owosho AA, Xu B, Kadempour A, Yom SK, Randazzo J, Ghossein RA, Hurn JM and Estilo CL: Metastatic solid tumors to the jaw and oral soft tissue: a retrospective clinical analysis of 44 patients from a single institution. J Craniomaxillofac Surg 44: 1047-1053, 2016.
12. Thrift AP, Wenker TN and El-Serag HB: Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol 20: 338-349, 2023.
13. Lund BA, Moertel CG and Gibilisco JA: Metastasis of gastric adenocarcinoma to oral mucosa. Oral Surg Oral Med Oral Pathol 25: 805-809, 1968.
14. Astacio JN and Alfaro C: Oral mucosa metastasis from gastric adenocarcinoma. Oral Surg Oral Med Oral Pathol 28: 859-861, 1969.
15. Ohba T, Nakagawa E and Nakata H: Metastatic tumor of the gum. Jpn J Cancer Clin 20: 692-696, 1974.
16. Lopez N and Lobos N: Metastatic adenocarcinoma of gingiva. Report of a case. J Periodontol 47: 358-360, 1976.
17. Osaki T, Ryoike K and Hamada T: Metastatic adenocarcinoma to the oral cavity: report of two cases and review of literature. Jpn J Stomatol Soc 27: 173-185, 1978.
18. Tojyo Y, Saito K, Aihara H, Tuda Y and Nisimaru Y: The metastasis of gastric adenocarcinoma to the gingiva of the mandible-review of the Japanese literature. Gan No Rinsho 35: 1165-1170, 1989 (In Japanese).
19. Hamakawa H, Takarada M and Tanioka H: Two metastatic tumors of the oral cavity: A histopathologic investigation. J Oral Surg Society Jpn 39: 823-828, 1993.
20. Florio SJ and Hurd TC: Gastric carcinoma metastatic to the mucosa of the hard palate. J Oral Maxillofac Surg 53: 1097-1098, 1995.
21. Makino S, Omura K and Kitada H: Metastatic mandibular tumor: Report of 7 cases. Jpn J Oral Maxillofac Surg 43: 465-472, 1997.
22. Yajima M and Miyazaki T: Metastasis of gastric adenocarcinoma to the maxillary gingiva: Report of a case. Jpn J Oral Maxillofac Surg 45: 497-499, 1999.
23. Shimoyama S, Seto Y, Aoki F, Ogawa T, Toma T, Endo H, Itouji T and Kaminishi M: Gastric cancer with metastasis to the gingiva. J Gastroenterol Hepatol 19: 831-835, 2004.
24. Colombo P, Tondulli L, Masci G, Muzza A, Rimassa L, Petrella D and Santoro A: Oral ulcer as an exclusive sign of gastric cancer: Report of a rare case. BMC Cancer 5: 117, 2005.

25. Kwon MS, Ko SO, Cho NP, Kim OH, Shin HK, Baek JA and Leem DH: Gastric signet-ring cell adenocarcinoma metastatic to the gingiva: A case report. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 102: 62-66, 2006.
26. Nishide N and Kanamura N: The value of carcinoembryonic antigen staining to determine the primary malignancy in metastatic carcinoma to the gingiva. *Am J Clin Oncol* 29: 316-317, 2006.
27. Hwang KG, Park CJ, Paik SS and Shim KS: Gingival metastasis from gastric adenocarcinoma. *Otolaryngol Head Neck Surg* 137: 169-170, 2007.
28. Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Kishino M, Hamab Y and Furukawa S: Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 107: e49-e53, 2009.
29. Sauerborn D, Vidakovic B, Baranovic M, Mahovne I, Danic P and Danic D: Gastric adenocarcinoma metastases to the alveolar mucosa of the mandible: A case report and review of the literature. *J Craniomaxillofac Surg* 39: 645-648, 2011.
30. Guo Y, Chen DF, Li P and CH L: Gingival metastasis from gastric cancer: 1 case report. *Chin J Gastmenterol* 17: 384, 2012.
31. Kalaitzidou IG, Astreidis IT, Kontos KI, Lazaridou MN, Bourlidou ET, Gerasimidou DK, Vladika NP and Mangoudi DL: Metastatic tumours to the oral cavity: Report of three cases. *J Oral Maxillofac Res* 6: e5, 2015.
32. Wu Z, Tang J, Li Y, Lu H, Xu J and Lv D: Successful management of rare gingival metastasis from gastric adenocarcinoma: A case report and literature review. *World J Surg Oncol* 15: 141, 2017.
33. Soares CD, Rocha BA, Paranaíba LMR, de Melo-Filho MR, Jorge J, de Carvalho MGF and de Almeida OP: A challenging diagnosis: Case report of oral metastasis from gastric adenocarcinoma mimicking pyogenic granuloma. *Medicine (Baltimore)* 97: e9934, 2018.
34. Ayşegül A, Ahmet K, Abdullah Y, Merva ST and Sidar B: Gastric carcinoma metastases to the anterior maxilla: A rare case report. *Int J Oral Med Sci* 17: 129-132, 2018.
35. Sohrabi C, Mathew G, Maria N, Kerwan A, Franchi T and Agha RA; Collaborators: The SCARE 2023 guideline: Updating consensus Surgical Case REport (SCARE) guidelines. *Int J Surg* 109: 1136-1140, 2023.
36. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma 2017. 15th edition. Kanehara Shuppan, Tokyo, 2017.
37. Japanese Gastric Cancer Association: Japanese gastric cancer treatment guidelines 2021. 6th edition. *Gastric Cancer* 26: 1-25, 2023.
38. Allon I, Pessing A, Kaplan I, Allon DM and Hirshberg A: Metastatic tumors to the gingiva and the presence of teeth as a contributing factor: A literature analysis. *J Periodontol* 85: 132-139, 2014.
39. Irani S: Metastasis to the oral soft tissues: A review of 412 cases. *J Int Soc Prev Community Dent* 6: 393-401, 2016.
40. Ellis GL, Jensen JL, Reingold IM and Barr RJ: Malignant neoplasms metastatic to gingivae. *Oral Surg Oral Med Oral Pathol* 44: 238-245, 1977.
41. Lok BH, Jiang G, Gutiontov S, Lanning RM, Sridhara S, Sherman EJ, Tsai CJ, McBride SM, Riaz N and Lee NY: Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. *Oral Oncol* 51: 957-962, 2015.
42. Toya R, Saito T, Yamaguchi K, Matsuyama T, Watakabe T, Matsumoto T, Yoshida R, Hirose A, Murakami D, Orita Y, *et al*: Hypofractionated palliative volumetric modulated arc radiotherapy with the radiation oncology study group 8502 'QUAD shot' regimen for incurable head and neck cancer. *Radiat Oncol* 15: 123, 2020.
43. Takahashi S, Endo M, Nagatomo T, Onaga R, Yamaguchi H, Yamamoto R, Fukuda Y, Ogawa K, Nakamura M, Okada K, *et al*: Successful preoperative QUAD SHOT for bulky parotid carcinoma: Potential preoperative ultra-hypofractionated radiotherapy for conversion surgery. *Case Rep Oncol* 16: 218-226, 2023.
44. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers (version 1). 2020.
45. Lee YH and Lee JI: Metastatic carcinoma of the oral region: An analysis of 21 cases. *Med Oral Patol Oral Cir Bucal* 22: e359-e365, 2017.



Copyright © 2025 Miyashita et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.